Merck price target raised to $123 from $116 at Guggenheim

Guggenheim raised the firm’s price target on Merck to $123 from $116 and keeps a Buy rating on the shares after updating the firm’s model following the "impressive results" for both sotatercept and MK-0616 shared at ACC earlier this week. Based on the STELLAR results and a preliminary check with key opinion leaders who called the data "amazing," "unbelievable" and "transformational," the firm has increased its sotatercept forecasts and now estimates peak sales of $7.2B in 2031 versus the $4.7B it has previously forecast.